ReviewCoronary heart disease and menopause management: The swinging pendulum of HRT
Introduction
Although clinical medicine tends to be an evolving process, one field in which there has been a dramatic change in prescribing patterns is the treatment of the postmenopausal woman. In the past 5 years, so much confusion and fear about hormone replacement therapy has emerged that patients and physicians have abandoned hormone replacement therapy or avoided this option, even in the most symptomatic healthy women at the onset of menopause [1]. Yet societies representing various medical groups are agreed that treatment of healthy women at the onset of menopause is appropriate [2], [3]. Why has there been so much confusion? We herewith provide an historical perspective regarding the reporting of the results of the Women's Health Initiative studies, and offer evidence that in the final analysis, the “final” results of the Women's Health Initiative are not different from data from the many observational studies that were available prior to Women's Health Initiative.
Section snippets
Women's Health Initiative trial designs
The Women's Health Initiative consisted of both a clinical trial and an observational study. The clinical trial consisted of three parts, hormone replacement therapy (estrogen and estrogen plus progestin arms comprising women randomized to active treatment or placebo), calcium and vitamin D supplementation, and low fat dietary modification. The Women's Health Initiative clinical trial was designed in 1991–1992 [4]. The results of the observational studies of the Women's Health Initiative, which
Coronary heart disease
The National Institutes of Health reported that “the adverse effects of estrogen plus progestin applied to all women irrespective of age, ethnicity, or prior disease state” [7]. They reported a statistically significant increase in heart attacks both in their press release and in the initial publication (Table 1) [4], [7]. This publication reported no trend with time and no noteworthy interaction with age on the coronary heart disease effects of hormone replacement therapy [4]. It was not
Breast cancer
In the initial report from the Women's Health Initiative estrogen plus progestin arm in 2002, breast cancers were confirmed by pathology reports “when available” and at the time of the initial publication at least 98% were available [4]. The incidence of breast cancer was initially reported as being statistically increased in the nominal but not the adjusted statistic (Table 3) [4]. In June 2003, the Women's Health Initiative presented the “centrally adjudicated” breast cancer data from the
Other clinical outcomes
Interestingly, in the Women's Health Initiative publication on gynecological cancers from the estrogen plus progestin arm, the authors concluded that estrogen plus progestin may increase the risk of ovarian cancer, yet they describe the endometrial cancer rates as similar to placebo, not as possibly decreased [24]. The differences between groups for both ovarian and endometrial cancer were not statistically significant [24].
The combined data on stroke showed an overall increase with hormones
Conclusions
In conclusion, the initial publication of the Women's Health Initiative hormone trial results has had a major impact on the management of postmenopausal women. Hormone replacement therapy has been vilified, both by prescribers and by regulatory authorities who appear to have accepted these results without question. Subsequent publications from the Women's Health Initiative with more complete results and analyses have cast doubt on the initial interpretation of the data. One of the most striking
Conflicts of interest
JCS has received research grants from Eli Lilly, Janssen-Cilag, Novo Nordisk, Organon, Schering, Shire, Solvay, Wyeth and the UK Medical Research Council, and has served on Advisory Boards and/or received honoraria for lectures from AstraZeneca, Bayer-Schering, Novo Nordisk, Orion, Proctor & Gamble, Servier, Solvay, Theramex and Wyeth. HNH is the Principal Investigator of the Early versus Late Intervention Trial with Estradiol (ELITE) funded by the NIH, R01AG-024154, and has served in the past
References (31)
- et al.
Approaches to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative
Control Clin Trials
(1996) - et al.
Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin
Maturitas
(2006) - et al.
Changes in U.S. prescribing patterns of menopausal hormone therapy, 2001–2003
Obstet Gynecol
(2006) - Cobin RH, Petak SM, Bledsoe MB, et al. American Association of Clinical Endocrinologists (AACE) position statement on...
- et al.
IMS updated recommendations on postmenopausal hormone therapy
Climacteric
(2007) - Writing group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy...
- et al.
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial
Am J Epidemiol
(2005) - et al.
Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease
Am J Epidemiol
(2006) - NHLBI stops trial of estrogen plus progestin due to increased breast cancer risk, Lack of Overall Benefit. National...
- Health risks outweigh benefits for combined estrogen plus progestin, clinical trial stopped early in major study. JAMA...
The war on (expensive) drugs
The Wall Street Journal
Estrogen plus progestin and the risk of coronary heart disease
N Engl J Med
A critique of Women's Health Initiative Studies (2002–2006)
Nucl Recept Signal
Cited by (56)
Effect of hormone replacement therapy on atherogenic lipid profile in postmenopausal women
2019, Thrombosis ResearchBack to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause
2016, AtherosclerosisCitation Excerpt :There has been much criticism about the results and interpretation of the findings in WHI and this discussion is beyond the scope of this review. The original results changed several time in terms of point estimates and confidence intervals, as reviewed by us previously [13]. In the most recent 13 year follow up of data from WHI, the early reported findings have been mainly negated.
Menopause
2016, International Encyclopedia of Public HealthEstrogen and the female heart
2014, Molecular and Cellular Endocrinology